Journal article
Scheduled versus Pro Re Nata Dosing in the VIEW Trials
Gisbert Richard, Jordi Mones, Sebastian Wolf, Jean Francois Korobelnik, Robyn Guymer, Michaella Goldstein, Christiane Norenberg, Rupert Sandbrink, Oliver Zeitz
OPHTHALMOLOGY | ELSEVIER SCIENCE INC | Published : 2015
Abstract
PURPOSE: To analyze visual acuity (VA) outcomes before and after preplanned treatment regimen change in the VIEW studies at week 52 (W52). DESIGN: Multiple post hoc analyses for retrospectively defined subgroups in 2 multicenter, multinational, double-masked trials. PARTICIPANTS: Two thousand four hundred fifty-seven neovascular age-related macular degeneration (AMD) patients. METHODS: Patients were randomized to treatment with 0.5 mg ranibizumab given monthly, a 0.5-mg or 2-mg intravitreal aflibercept injection given monthly, or 2 mg intravitreal aflibercept given every other month, after 3 initial monthly doses, up to W52. From W52 through W96, patients received their original dosing assig..
View full abstractGrants
Funding Acknowledgements
The author(s) have made the following disclosure(s): G.R.: Financial support - Bayer HealthCare (Berlin, Germany), Pfizer (Cambridge, MA), Carl Zeiss Meditec (Jena, Germany), Novartis AG (Basel, Switzerland), Pixium Vision (Paris, France); Consultant - Carl Zeiss Meditec (Jena, Germany), Pixium Vision (Paris, France).